Literature DB >> 29322939

Public health psychopharmacology: a new research discipline comes of age?

C Barbui1, G Ostuzzi1, B Godman2.   

Abstract

Research evidence guiding the identification of pragmatic and effective actions aimed at improving the selection, availability, affordability and rational prescribing of medicines for mental disorders is sparse and inconsistent. In order to boost the development of new research, in this commentary we suggest to organise and classify all the activities in this area under a common theoretical framework and nomenclature, adopting the term 'public health psychopharmacology'. Public health psychopharmacology is proposed as a research discipline, based on contributions from the fields of regulatory science, health services research and implementation science. Implementing the term public health psychopharmacology may offer advantages, as the scientific community would be more focused on common goals and objectives, with, likely, an increasing body of research evidence of practical use.

Entities:  

Keywords:  Affordability; availability; psychotropic medicines; rational prescribing; selection of medicines

Mesh:

Substances:

Year:  2018        PMID: 29322939      PMCID: PMC6998875          DOI: 10.1017/S2045796017000464

Source DB:  PubMed          Journal:  Epidemiol Psychiatr Sci        ISSN: 2045-7960            Impact factor:   6.892


  13 in total

Review 1.  Adherence to medication.

Authors:  Lars Osterberg; Terrence Blaschke
Journal:  N Engl J Med       Date:  2005-08-04       Impact factor: 91.245

2.  Non-inferiority trials are unethical because they disregard patients' interests.

Authors:  Silvio Garattini; Vittorio Bertele'
Journal:  Lancet       Date:  2007-10-23       Impact factor: 79.321

3.  Regulatory science in Europe: the case of schizophrenia trials.

Authors:  Corrado Barbui; Irene Bighelli
Journal:  Lancet       Date:  2013-06-21       Impact factor: 79.321

4.  Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications.

Authors:  Menno van Woerkom; Hans Piepenbrink; Brian Godman; Joost de Metz; Stephen Campbell; Marion Bennie; Marietta Eimers; Lars L Gustafsson
Journal:  J Comp Eff Res       Date:  2012-11       Impact factor: 1.744

5.  Mapping actions to improve access to medicines for mental disorders in low and middle income countries.

Authors:  C Barbui; T Dua; K Kolappa; B Saraceno; S Saxena
Journal:  Epidemiol Psychiatr Sci       Date:  2017-01-09       Impact factor: 6.892

6.  New EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence base.

Authors:  G Ostuzzi; D Papola; C Gastaldon; C Barbui
Journal:  Epidemiol Psychiatr Sci       Date:  2016-12-22       Impact factor: 6.892

7.  Access to psychotropic medicines in low-resource settings.

Authors:  Corrado Barbui; Tarun Dua; Kavitha Kolappa; Benedetto Saraceno; Shekhar Saxena
Journal:  Lancet Psychiatry       Date:  2016-10       Impact factor: 27.083

8.  The prevalence of antipsychotic polypharmacy in schizophrenic patients discharged from psychiatric units in Poland.

Authors:  Jan Jaracz; Edyta Tetera-Rudnicka; Dominika Kujath; Agnieszka Raczyńska; Sebastian Stoszek; Wojciech Czernaś; Piotr Wierzbiński; Adam Moniakowski; Krystyna Jaracz; Janusz Rybakowski
Journal:  Pharmacol Rep       Date:  2014-04-25       Impact factor: 3.024

Review 9.  Can systematic reviews contribute to regulatory decisions?

Authors:  Corrado Barbui; Antonio Addis; Laura Amato; Giuseppe Traversa; Silvio Garattini
Journal:  Eur J Clin Pharmacol       Date:  2017-01-07       Impact factor: 2.953

10.  Prevalence and appropriateness of psychotropic medication prescribing in a nationally representative cross-sectional survey of male and female prisoners in England.

Authors:  Lamiece Hassan; Jane Senior; Roger T Webb; Martin Frisher; Mary P Tully; David While; Jenny J Shaw
Journal:  BMC Psychiatry       Date:  2016-10-10       Impact factor: 3.630

View more
  1 in total

1.  Medicine-based evidence: the case of antidepressants in patients with coronary artery disease.

Authors:  C Barbui; G Ostuzzi
Journal:  Epidemiol Psychiatr Sci       Date:  2018-07-30       Impact factor: 6.892

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.